Medicine
Trijardy XR 12.5 mg/2.5 mg/1000 mg extended-release tablet
Trijardy XR 12.5 mg/2.5 mg/1000 mg extended-release tablet is a prescription medicine containing Empagliflozin, Linagliptin and Metformin for oral use, marketed by Boehringer Ingelheim Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Empagliflozin, Linagliptin and Metformin
- Brand
- Trijardy XR
- Strength
- 12.5 mg/2.5 mg/1000 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 60 tablets, 180 tablets
- Marketing authorisation holder
- Boehringer Ingelheim Pharmaceuticals
- Manufacturer
- Boehringer Ingelheim Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from exposure to high humidity.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 April 2020
- Identifiers
- RxCUI 2359279, 2359285, 2359288 +5DailyMed set ID 71873567-9594-452a-bb92-34a129adecacNDC 0597-0385Application NDA212614
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 60 tablet, extended release in 1 bottle | 0597-0385-77 | Boehringer Ingelheim Pharmaceuticals | 23 April 2020 |
| 180 tablet, extended release in 1 bottle | 0597-0385-86 | Boehringer Ingelheim Pharmaceuticals | 23 April 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 27 January 2020 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Empagliflozin, Linagliptin and Metformin
Clinical summary
Empagliflozin, Linagliptin and Metformin is a fixed-dose combination of a biguanide, a dipeptidyl peptidase 4 inhibitor and a sodium-glucose cotransporter 2 inhibitor. It is available as extended-release tablets for oral use. MedsAcross supplies Empagliflozin, Linagliptin and Metformin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Empagliflozin, Linagliptin and MetforminFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Trijardy XR prescribing information (Boehringer Ingelheim Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Trijardy XR 12.5 mg/2.5 mg/1000 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.